CLINICAL TRIALS PROFILE FOR LANSOPRAZOLE
✉ Email this page to a colleague
All Clinical Trials for LANSOPRAZOLE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00149084 ↗ | Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori | Unknown status | Yokoyama Foundation for Clinical Pharmacology | Phase 3 | 2003-04-01 | The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy. |
| NCT00149084 ↗ | Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori | Unknown status | Hamamatsu University | Phase 3 | 2003-04-01 | The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy. |
| NCT00174928 ↗ | A Study to Evaluate the Effect of Lansoprazole on Hospitalized Neonates With Gastroesophageal Reflux Disease | Completed | Takeda | Phase 1 | 2005-05-01 | The purpose of this study is to understand how quickly lansoprazole, once daily (QD), improves feeding in premature babies or babies less than 28 days of age. |
| NCT00175032 ↗ | A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin | Completed | Takeda | Phase 3 | 2003-07-01 | The purpose of this study is to compare the gastroduodenal ulceration rate, gastrointestinal complication rate and non-steroidal anti-inflammatory drug-associated dyspepsia between lansoprazole, naproxen and celecoxib, taken once daily (QD) or twice daily (BID), in participants with osteoarthritis taking low dose aspirin. |
| NCT00175045 ↗ | Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis | Completed | Takeda | Phase 2 | 2003-06-01 | The purpose of this study was to compare the pharmacodynamics of intravenous (IV) lansoprazole to oral lansoprazole capsules, once daily (QD), in participants with erosive esophagitis. |
| NCT00204373 ↗ | Treatment of Zollinger-Ellison Syndrome With Prevacid | Completed | Takeda Pharmaceuticals North America, Inc. | Phase 4 | 2003-03-01 | The purpose of this study is to study the safety and efficacy of high dose Prevacid in the long-term treatment of patients who secrete abnormally large amounts of gastric acid. |
| NCT00204373 ↗ | Treatment of Zollinger-Ellison Syndrome With Prevacid | Completed | Charles Mel Wilcox, MD | Phase 4 | 2003-03-01 | The purpose of this study is to study the safety and efficacy of high dose Prevacid in the long-term treatment of patients who secrete abnormally large amounts of gastric acid. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LANSOPRAZOLE
Condition Name
Clinical Trial Locations for LANSOPRAZOLE
Trials by Country
Clinical Trial Progress for LANSOPRAZOLE
Clinical Trial Phase
Clinical Trial Sponsors for LANSOPRAZOLE
Sponsor Name
